Benitec Biopharma Inc. Other Assets
Benitec Biopharma Inc. (BNTC) had Other Assets of $1.61 million as of 2026-06-30, per its 10-K filed 2026-09-14.
Financial Statements › Balance Sheet › Assets
us-gaap:OtherAssets · last filed 2026-09-14
- 2026-06-30: Other Assets $1.61M.
- 2026-03-31: Other Assets $1.15M.
- 2025-12-31: Other Assets $573.00K.
- 2025-09-30: Other Assets $500.00K.
| Period end | Other Assets | Other Assets as first filed |
|---|---|---|
| 2026-06-30 | $1.61M 10-K · filed 2026-09-14 | |
| 2026-03-31 | $1.15M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $573.00K 10-Q · filed 2026-02-12 | |
| 2025-09-30 | $500.00K 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $656.00K 10-K · filed 2026-09-14 | |
| 2025-03-31 | $396.00K 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $408.00K 10-Q · filed 2025-02-14 | |
| 2024-09-30 | $482.00K 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $578.00K 10-K/A · filed 2026-03-20 | |
| 2024-03-31 | $226.00K 10-Q · filed 2024-05-13 | |
| 2023-12-31 | $436.00K 10-Q · filed 2024-02-13 | |
| 2023-09-30 | $567.00K 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $1.28M 10-K · filed 2024-09-26 | |
| 2023-03-31 | $879.00K 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $472.00K 10-Q · filed 2023-02-13 | |
| 2022-09-30 | $650.00K 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $876.00K 10-K · filed 2023-09-21 | |
| 2022-03-31 | $362.00K 10-Q · filed 2022-05-16 | |
| 2021-12-31 | $499.00K 10-Q · filed 2022-02-14 | |
| 2021-09-30 | $811.00K 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $984.00K 10-K · filed 2022-09-02 | $999.00K 10-K · filed 2021-09-20 |
| 2021-03-31 | $606.00K 10-Q · filed 2021-05-12 | |
| 2020-12-31 | $562.00K 10-Q · filed 2021-02-09 | |
| 2020-06-30 | $949.00K 10-K · filed 2021-09-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |